Mankind Pharma Q2 FY27 Results: Revenue ₹8,366 Crore, Profit ₹1,698 Crore
Mankind Pharma reported consolidated revenue of ₹8,366.45 crore and profit after tax of ₹1,290.21 crore for H1 FY27. Standalone revenue was ₹6,109.27 crore with profit after tax of ₹1,140.44 crore for the same period. Basic EPS stood at ₹30.99 on a standalone basis.
Financial results, especially revenue and profit figures, are material information for investors and significantly impact the company's stock price and market perception.
The financial results show growth in revenue and profit for both consolidated and standalone operations, indicating a positive performance for the company.
Mankind Pharma Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported consolidated revenue from operations of ₹8,366.45 crore for the six months ended September 30, 2026, a significant increase from ₹7,267.51 crore in the corresponding period of the previous year.
For the quarter ended September 30, 2026, consolidated revenue stood at ₹4,337.86 crore. Consolidated profit before exceptional items and tax for the six months was ₹1,698.56 crore, and profit after tax was ₹1,290.21 crore. The basic Earnings Per Share (EPS) for the six-month period was ₹30.99.
On a standalone basis, revenue from operations for the six months ended September 30, 2026, was ₹6,109.27 crore. Standalone profit before exceptional items and tax for the period was ₹1,540.16 crore, with profit after tax at ₹1,140.44 crore. The standalone basic EPS for the six months was ₹30.99.
The Board of Directors approved these unaudited financial results at their meeting held on October 26, 2026. The detailed financial results are available on the company's website and the websites of the stock exchanges.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.